Overview: HOMA-Beta TestIntroduction: The HOMA-Beta Test measures beta-cell function to assess insulin production in diabetes, helping manage blood sugar control and guide treatment. Affecting 1 in 10 people with diabetes, beta-cell dysfunction poses diagnostic challenges due to progressive decline. Following 2023 American Diabetes Association (ADA) guidelines, it uses calculation based on insulin and glucose for high accuracy, supporting endocrinology screening. This test is essential for diagnosis, therapy planning, and improving outcomes in endocrinology.
Other Names: Beta-Cell Function Test, HOMA-Beta Index Assay.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic reliability.
Historical Milestone: HOMA modeling began in the 1980s with research by Matthews, who developed the index. Calculation refinements in the 2000s by the ADA improved application, surpassing earlier insulin assays.
Purpose: Measures HOMA-Beta index to assess beta-cell function, guides insulin therapy, and evaluates patients with high blood sugar, aiming to prevent complications.
Test Parameters: HOMA-Beta index
Pretest Condition: Fasting required to reflect baseline levels. Collect serum or plasma. Report history of diabetes.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document high blood sugar or diabetes history. Include current medications or diet.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., neuropathy), and sample collection risks.
Procedural Considerations: Uses calculation based on insulin and glucose levels, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample hemolysis can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Low index confirms beta-cell dysfunction, guiding therapy. Early intervention might prevent progression, while untreated cases lead to complications. Normal levels may require glucose tolerance test.
Specialist Consultation: Consult an endocrinologist for interpretation.
Additional Supporting Tests: Fasting glucose, HbA1c, or C-peptide to confirm diagnosis.
Test Limitations: Indirect measure; correlation with clinical status needed. False results possible with insulin resistance.
References: ADA Guidelines, 2023; Diabetologia, Matthews DR, 2022.
